Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation

Roderich E. Schwarz, Niranjan Awasthi, Srivani Konduri, Lauren Caldwell, Danielle Cafasso, Margaret A. Schwarz

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is highly resistant to conventional chemotherapy. The presence of both cellular and stromal fibronectin (FN) and its interaction with integrins is necessary for PDAC progression. We tested the efficacy of endothelial monocyte-activating polypeptide II (EMAP II) to inhibit PDAC progression and its ability to interfere with FN-integrin angiogenesis signaling. In heterotopic PDAC tumors EMAP II caused a significant reduction (>65%) in tumor growth, accompanied by a >50% and 44% decrease in microvessel density and proliferative activity, respectively. EMAP II therapy caused a 62% and 56% reduction in host and tumor cell FN expression. Cultured PDAC cells expressed αVβ3 and α5β1 integrins. In vitro EMAP II had limited antiproliferative effects on ASPC-1, but a pronounced antiproliferative effect on endothellial cells. 3D FN matrices increased ASPC-1 cell proliferation by >50%, and this induction was significantly blocked by α3, α5, α6 and αV integrin funtional blocking antibodies, while α1, α2 and α4 antibodies had no effect. EMAP II also inhibited 3D FN-matrix induced ASPC-1 proliferation by >43% at 20 μM. These findings suggest that EMAP II demonstrates significant antitumor activity against PDAC cells, and that this effect may be in part mediated through targeted interference with stromal FN-integrin dependent PDAC cell proliferation.

Original languageEnglish (US)
Pages (from-to)632-639
Number of pages8
JournalCancer Biology and Therapy
Volume9
Issue number8
StatePublished - Apr 15 2010

Fingerprint

Pancreatic Neoplasms
Fibronectins
Adenocarcinoma
Integrins
Cell Proliferation
Neoplasms
Blocking Antibodies
Microvessels
small inducible cytokine subfamily E, member 1
Drug Therapy
Antibodies
Growth

Keywords

  • Cell proliferation
  • EMAP II
  • Fibronectin
  • Integrin
  • Pancreatic cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Molecular Medicine
  • Pharmacology

Cite this

Schwarz, R. E., Awasthi, N., Konduri, S., Caldwell, L., Cafasso, D., & Schwarz, M. A. (2010). Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation. Cancer Biology and Therapy, 9(8), 632-639.

Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation. / Schwarz, Roderich E.; Awasthi, Niranjan; Konduri, Srivani; Caldwell, Lauren; Cafasso, Danielle; Schwarz, Margaret A.

In: Cancer Biology and Therapy, Vol. 9, No. 8, 15.04.2010, p. 632-639.

Research output: Contribution to journalArticle

Schwarz, RE, Awasthi, N, Konduri, S, Caldwell, L, Cafasso, D & Schwarz, MA 2010, 'Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation', Cancer Biology and Therapy, vol. 9, no. 8, pp. 632-639.
Schwarz RE, Awasthi N, Konduri S, Caldwell L, Cafasso D, Schwarz MA. Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation. Cancer Biology and Therapy. 2010 Apr 15;9(8):632-639.
Schwarz, Roderich E. ; Awasthi, Niranjan ; Konduri, Srivani ; Caldwell, Lauren ; Cafasso, Danielle ; Schwarz, Margaret A. / Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation. In: Cancer Biology and Therapy. 2010 ; Vol. 9, No. 8. pp. 632-639.
@article{824c41442ca4490f99d00152acb433e4,
title = "Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation",
abstract = "Pancreatic ductal adenocarcinoma (PDAC) is highly resistant to conventional chemotherapy. The presence of both cellular and stromal fibronectin (FN) and its interaction with integrins is necessary for PDAC progression. We tested the efficacy of endothelial monocyte-activating polypeptide II (EMAP II) to inhibit PDAC progression and its ability to interfere with FN-integrin angiogenesis signaling. In heterotopic PDAC tumors EMAP II caused a significant reduction (>65{\%}) in tumor growth, accompanied by a >50{\%} and 44{\%} decrease in microvessel density and proliferative activity, respectively. EMAP II therapy caused a 62{\%} and 56{\%} reduction in host and tumor cell FN expression. Cultured PDAC cells expressed αVβ3 and α5β1 integrins. In vitro EMAP II had limited antiproliferative effects on ASPC-1, but a pronounced antiproliferative effect on endothellial cells. 3D FN matrices increased ASPC-1 cell proliferation by >50{\%}, and this induction was significantly blocked by α3, α5, α6 and αV integrin funtional blocking antibodies, while α1, α2 and α4 antibodies had no effect. EMAP II also inhibited 3D FN-matrix induced ASPC-1 proliferation by >43{\%} at 20 μM. These findings suggest that EMAP II demonstrates significant antitumor activity against PDAC cells, and that this effect may be in part mediated through targeted interference with stromal FN-integrin dependent PDAC cell proliferation.",
keywords = "Cell proliferation, EMAP II, Fibronectin, Integrin, Pancreatic cancer",
author = "Schwarz, {Roderich E.} and Niranjan Awasthi and Srivani Konduri and Lauren Caldwell and Danielle Cafasso and Schwarz, {Margaret A.}",
year = "2010",
month = "4",
day = "15",
language = "English (US)",
volume = "9",
pages = "632--639",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "8",

}

TY - JOUR

T1 - Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation

AU - Schwarz, Roderich E.

AU - Awasthi, Niranjan

AU - Konduri, Srivani

AU - Caldwell, Lauren

AU - Cafasso, Danielle

AU - Schwarz, Margaret A.

PY - 2010/4/15

Y1 - 2010/4/15

N2 - Pancreatic ductal adenocarcinoma (PDAC) is highly resistant to conventional chemotherapy. The presence of both cellular and stromal fibronectin (FN) and its interaction with integrins is necessary for PDAC progression. We tested the efficacy of endothelial monocyte-activating polypeptide II (EMAP II) to inhibit PDAC progression and its ability to interfere with FN-integrin angiogenesis signaling. In heterotopic PDAC tumors EMAP II caused a significant reduction (>65%) in tumor growth, accompanied by a >50% and 44% decrease in microvessel density and proliferative activity, respectively. EMAP II therapy caused a 62% and 56% reduction in host and tumor cell FN expression. Cultured PDAC cells expressed αVβ3 and α5β1 integrins. In vitro EMAP II had limited antiproliferative effects on ASPC-1, but a pronounced antiproliferative effect on endothellial cells. 3D FN matrices increased ASPC-1 cell proliferation by >50%, and this induction was significantly blocked by α3, α5, α6 and αV integrin funtional blocking antibodies, while α1, α2 and α4 antibodies had no effect. EMAP II also inhibited 3D FN-matrix induced ASPC-1 proliferation by >43% at 20 μM. These findings suggest that EMAP II demonstrates significant antitumor activity against PDAC cells, and that this effect may be in part mediated through targeted interference with stromal FN-integrin dependent PDAC cell proliferation.

AB - Pancreatic ductal adenocarcinoma (PDAC) is highly resistant to conventional chemotherapy. The presence of both cellular and stromal fibronectin (FN) and its interaction with integrins is necessary for PDAC progression. We tested the efficacy of endothelial monocyte-activating polypeptide II (EMAP II) to inhibit PDAC progression and its ability to interfere with FN-integrin angiogenesis signaling. In heterotopic PDAC tumors EMAP II caused a significant reduction (>65%) in tumor growth, accompanied by a >50% and 44% decrease in microvessel density and proliferative activity, respectively. EMAP II therapy caused a 62% and 56% reduction in host and tumor cell FN expression. Cultured PDAC cells expressed αVβ3 and α5β1 integrins. In vitro EMAP II had limited antiproliferative effects on ASPC-1, but a pronounced antiproliferative effect on endothellial cells. 3D FN matrices increased ASPC-1 cell proliferation by >50%, and this induction was significantly blocked by α3, α5, α6 and αV integrin funtional blocking antibodies, while α1, α2 and α4 antibodies had no effect. EMAP II also inhibited 3D FN-matrix induced ASPC-1 proliferation by >43% at 20 μM. These findings suggest that EMAP II demonstrates significant antitumor activity against PDAC cells, and that this effect may be in part mediated through targeted interference with stromal FN-integrin dependent PDAC cell proliferation.

KW - Cell proliferation

KW - EMAP II

KW - Fibronectin

KW - Integrin

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=77953695153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953695153&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 632

EP - 639

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 8

ER -